PLx Pharma (PLXP) Reports Q1 Revenue of $2.1M, EPS of ($0.66)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St declines as oil prices, Treasury yields remain elevated
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Oppenheimer sees AI software winners as focus shifts to ROI
- Arm Holdings falls as CFO stock sale weighs on sentiment
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
PLx Pharma Inc. Reports First Quarter 2022 Results and Provides Business Update
May 13, 2022 6:50 AM EDTBUILDING A SOLID BASE OF VAZALORE® USERS
Total Net Sales of $2.1 Million in the First Quarter of 2022, an Increase of Approximately 31% from Fourth Quarter of 2021GAAP Net Loss of ($0.39) Per Diluted Share in the First Quarter 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.66) Cash & Cash Equivalent Balance of $52.5 Million as of March 31, 2022Disciplined Spending to Support Strategic GrowthSPARTA, N.J., May 13, 2022 (GLOBE... More
